The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

Jim Cramer, a stalwart of stock market commentary, recently shifted gears on Bristol-Myers Squibb, pegging his hopes on their ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

A new genetic test, based on data from more than five million people, can identify people at risk of severe obesity. The test can be performed on children before their genetic risk starts to shape ...

BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call ...

Our warm weather season is short, and it’s important to enjoy the outdoors. The point isn’t to be sun-scared — just stay ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.